We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thales AVS France

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Ultrasound Technology Helps Dissolve Blood Clots

By MedImaging International staff writers
Posted on 19 Jun 2014
Print article
Image: The EkoSonic IDDC and removable coaxial ultrasound transducer core (Photo courtesy of EKOS Corporation).
Image: The EkoSonic IDDC and removable coaxial ultrasound transducer core (Photo courtesy of EKOS Corporation).
A new system allows controlled and selective infusion of physician-specified fluids, including thrombolytics, for the treatment of pulmonary embolism (PE).

The EkoSonic Endovascular System is an ultrasound-facilitated catheter-directed low-dose fibrinolysis device designed to gently accelerate the penetration of thrombolytic agents into a thrombus, providing high levels of lysis to minimize the risk of PE and intracranial hemorrhage. The system is intended for the treatment of patients with a 50% or more clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, as well as evidence of right heart dysfunction, based on a mean pulmonary artery pressure of 25 mmHg or higher, and/or echocardiographic evaluation.

The device consists of a multilumen intelligent drug delivery catheter (IDDC) with a removable coaxial ultrasound transducer core and a microsonic device (MSD). The acoustic energy conditions the clot by thinning fibrin and increasing porosity, creating a pressure gradient which transports the thrombolytic agent deep into the thrombus. As a result, there is no thrombus fracture or breakage, no damage to valves or the vascular wall, and no hemolysis.

An added benefit is that since red blood cells (RBCs) are not fractured during the procedure, there is no adenosine release and no additional compromise to renal function. The EkoSonic Endovascular System is a product of EKOS Corporation (Bothell, WA, USA), and has been approved by the US Food and Drug Administration (FDA).

“The EKOS clinical data established that patients stricken with a life-threatening pulmonary embolism can be successfully and safely treated with the EkoSonic system,” said Prof. Samuel Goldhaber, MD, director of the Thrombosis Research Group at Brigham and Woman’s Hospital (Boston, MA, USA). “This is the first FDA cleared treatment option for PE since the approval of the drug tissue plasminogen activator [tPA], in 1990.”

“Interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use our system to provide faster, safer and more complete dissolution of thrombus,” said Matt Stupfel, General Manager of EKOS. “We are proud to have completed the world’s only randomized controlled trial and the largest prospective single-arm trial on the safety and effectiveness of EKOS therapy in the treatment of PE. The positive outcomes of those trials, combined with our expanded indication will allow a better standard of care for thousands of patients who suffer from PE.”

Related Links:

EKOS Corporation



Print article
CIRS
Sun Nuclear

Channels

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel
Image: GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health (Photo courtesy of GE Healthcare)

GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health

General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023. The spin-off of GE Healthcare... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.